Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Perspective Therapeutics, Inc.CATX · healthcare | |
|---|---|
| Grade |  C/Don the C/D boundary of 371 graded peers; percentile 60.3, sampling error 2.5 points; lower is stronger |
| Rank | 224 of 371 |
| Profitability | Dpercentile 69.9 |
| Solvency | Cpercentile 43.9 |
| Growth and financing | B/Cpercentile 41.1 |
| Reliability | 0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| Peer failure rate | 1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $120M to $591M assetstotal assets $267.0M[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | dilution · fortress balance sheet |
| Inputs computable | 7 of 14 |
| Graded from | filings received through Mar 16, 2026207 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $2.712026-10-08; market equity $309.9M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 16, 2026; the document on sec.gov.
We are a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. We have proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. We are also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
Warnings [top]
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 69.9 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31 | |||||||
| Return on invested capital | (55.1%) | [5-13] | 9.3% | 84.9 | 74 | 2025-12-31 | |
| Accruals ratio | (6.8%) | [1,14-16] | (6.6%) | 54.8 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five consecutive annual gross margins are required | |||||||
| Solvency, sleeve percentile 43.9 | |||||||
| Twelve-month failure probability | 0.10% | 0.07% | 57.9 | 248 | 2026-06-30 | ||
| Altman Z double-prime | (0.38) | [1,7,10,17-20] | (0.31) | 38.4 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| EBITDA must exceed $100,000 | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| interest expense must exceed $100,000 | |||||||
| Current ratio | 5.17x | [17-18] | 2.96x | 35.3 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 41.1 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four consecutive annual observations are required | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| four consecutive annual FCF observations are required; found 14 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| NOPAT must exceed $100,000 | |||||||
| Asset growth, three years | 66.3% | [1,16,21-22] | 2.1% | 5.1 | 704 | 2025-12-31 | |
| Net share issuance, one year | 53.9% | [3-4] | 2.5% | 77.1 | 634 | 2026-03-12 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite 0.033; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 219 | Option Care Health, Inc. (OPCH) Option Care Health, Inc. (OPCH) C/Don the C/D boundary; percentile 58.9 Nasdaq · Services-Home Health Care Services market equity $4.9B; last close $31.06 No active warnings; 12 of 14 inputs | 58.9 | C/D | |
| 220 | Cryoport, Inc. (CYRX) Cryoport, Inc. (CYRX) C/Don the C/D boundary; percentile 59.2 Nasdaq · Pharmaceutical Preparations market equity $856.0M; last close $16.91 Warnings: late filer; 9 of 14 inputs | 59.2 | C/D | late filer |
| 221 | GeneDx Holdings Corp. (WGS) GeneDx Holdings Corp. (WGS) C/Don the C/D boundary; percentile 59.5 Nasdaq · Services-Health Services market equity $2.0B; last close $67.69 Warnings: fortress balance sheet; 10 of 14 inputs | 59.5 | C/D | fortress balance sheet |
| 222 | Trulieve Cannabis Corp. (TRLV) Trulieve Cannabis Corp. (TRLV) C/Don the C/D boundary; percentile 59.7 NYSE · Medicinal Chemicals & Botanical Products market equity $2.0B; last close $10.40 Warnings: fortress balance sheet; 7 of 14 inputs | 59.7 | C/D | fortress balance sheet |
| 223 | Labcorp Holdings Inc. (LH) Labcorp Holdings Inc. (LH) C/Don the C/D boundary; percentile 60.0 NYSE · Services-Medical Laboratories market equity $25.5B; last close $314.20 No active warnings; 10 of 14 inputs | 60.0 | C/D | |
| 224 | Perspective Therapeutics, Inc. (CATX) Perspective Therapeutics, Inc. (CATX) C/Don the C/D boundary; percentile 60.3 NYSE · Pharmaceutical Preparations market equity $309.4M; last close $2.71 Warnings: dilution, fortress balance sheet; 7 of 14 inputs | 60.3 | C/D | dilution, fortress balance sheet |
| 225 | ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals, Inc. (SPRY) C/Don the C/D boundary; percentile 60.5 Nasdaq · Pharmaceutical Preparations market equity $453.5M; last close $4.57 Warnings: short runway; 7 of 14 inputs | 60.5 | C/D | short runway |
| 226 | Twist Bioscience Corp. (TWST) Twist Bioscience Corp. (TWST) C/Don the C/D boundary; percentile 60.8 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $9.5B; last close $152.02 Warnings: fortress balance sheet; 9 of 14 inputs | 60.8 | C/D | fortress balance sheet |
| 227 | Teva Pharmaceutical Industries Ltd. (TEVA) Teva Pharmaceutical Industries Ltd. (TEVA) C/Don the C/D boundary; percentile 61.1 NYSE · Pharmaceutical Preparations market equity $45.7B; last close $39.22 No active warnings; 9 of 14 inputs | 61.1 | C/D | |
| 228 | Beam Therapeutics Inc. (BEAM) Beam Therapeutics Inc. (BEAM) C/Don the C/D boundary; percentile 61.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $2.5B; last close $24.59 No active warnings; 7 of 14 inputs | 61.4 | C/D | |
| 229 | Akebia Therapeutics, Inc. (AKBA) Akebia Therapeutics, Inc. (AKBA) C/Don the C/D boundary; percentile 61.6 Nasdaq · Pharmaceutical Preparations market equity $225.8M; last close $0.82 Warnings: fortress balance sheet; 9 of 14 inputs | 61.6 | C/D | fortress balance sheet |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | D | 66.1 | 2204 |
| sector peers, equal sleeves (the grade) | C/D | 60.3 | 371 |
| same exchange, equal sleeves | D | 69.8 | 984 |
| sector peers, equal inputs | C/D | 58.4 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (7.9%) | 8.0% | 41 | hotter than 41 of 100 peers |
| Distance from 52-week high | (52.0%) | (31.4%) | 25 | closer to its high than 25 of 100 peers |
| EBIT to enterprise value | (43.3%) | (1.5%) | 16 | pricier than 84 of 100 peers |
| Free cash flow yield | (30.8%) | (1.0%) | 18 | pricier than 82 of 100 peers |
| Book value to price | 1.05 | 0.28 | 87 | pricier than 13 of 100 peers |
| Sales to price | 0.00 | 0.31 | 5 | pricier than 95 of 100 peers |
| Composite equity issuance, five years | 280.7% | 20.3% | 95 | more equity-funded than 95 of 100 peers |
| Relative strength against the sector, log excess return | (0.29) | (0.14) | 41 | ahead of 41 of 100 peers |
Inputs: market equity $309.4M; EBIT -$113.6M; free cash flow -$95.2M; book equity $323.9M; sales $1.4M; debt $1.6M; cash $48.5M[23].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (30.2%) | ✗ fail[14,16] |
| Operating cash flow above zero | -$82.5M | ✗ fail[15] |
| Return on assets improved | 50.8 pts | ✓ pass[14,16,21,24] |
| Operating cash flow exceeds net income | $20.6M | ✓ pass[14-15] |
| Long-term leverage fell | (0.2 pts) | ✓ pass[1,6,11,16,21] |
| Current ratio improved | (750.6 pts) | ✗ fail[17-18,25-26] |
| No new shares issued | 53.9% | ✗ fail[3-4] |
| Gross margin improved | n/a | |
| Asset turnover improved | n/a[16,21] | |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $267.0M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax | $1.4M | 2023-12-31 | 2024-03-28 | 10-K | filing · viewer · series |
| 3 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 113,933,436 | 2026-03-12 | 2026-03-16 | 10-K | filing · viewer · series |
| 4 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 74,051,841 | 2025-03-21 | 2025-03-28 | 10-K/A | filing · viewer · series |
| 5 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $30.6M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 6 | total debt | us-gaap:LongTermDebt | $1.6M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 7 | operating income | us-gaap:OperatingIncomeLoss | -$113.6M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 8 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | -$104.4M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 9 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$793,000 | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 10 | book equity | us-gaap:StockholdersEquity | $207.0M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 11 | total debt | us-gaap:LongTermDebt | $1.7M | 2024-12-31 | 2025-03-28 | 10-K/A | filing · viewer · series |
| 12 | book equity | us-gaap:StockholdersEquity | $290.7M | 2024-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 13 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $61.6M | 2024-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 14 | net income | us-gaap:NetIncomeLoss | -$103.1M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 15 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$82.5M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 16 | assets | us-gaap:Assets | $341.1M | 2024-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 17 | current assets | us-gaap:AssetsCurrent | $148.4M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 18 | current liabilities | us-gaap:LiabilitiesCurrent | $28.7M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 19 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$334.8M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 20 | liabilities | us-gaap:Liabilities | $59.9M | 2025-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 21 | assets | us-gaap:Assets | $97.9M | 2023-12-31 | 2025-03-28 | 10-K/A | filing · viewer · series |
| 22 | assets | us-gaap:Assets | $58.1M | 2022-12-31 | 2024-03-28 | 10-K | filing · viewer · series |
| 23 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 114,151,663 | 2026-08-05 | 2026-08-10 | 10-Q | filing · viewer · series |
| 24 | net income | us-gaap:NetIncomeLoss | -$79.3M | 2024-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 25 | current assets | us-gaap:AssetsCurrent | $231.2M | 2024-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 26 | current liabilities | us-gaap:LiabilitiesCurrent | $18.2M | 2024-12-31 | 2026-03-16 | 10-K | filing · viewer · series |
| 27 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $48.5M | 2026-06-30 | 2026-08-10 | 10-Q | filing · viewer · series |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$52.1M | 2026-06-30 | 2026-08-10 | 10-Q | filing · viewer · series |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$31.5M | 2026-03-31 | 2026-05-11 | 10-Q | filing · viewer · series |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$57.8M | 2025-09-30 | 2025-11-10 | 10-Q | filing · viewer · series |
| 31 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$41.5M | 2025-06-30 | 2026-08-10 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 60.3 is 0.3 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
